| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/14/2009 | US7560440 Endothelial growth factors; antiischemic agents; neovascularization |
| 07/14/2009 | US7560438 Genetic inhibition by double-stranded RNA |
| 07/14/2009 | US7560437 Therapeutic agent for use in the diagnosis and treatment of cancer and cell proliferative disorders |
| 07/14/2009 | US7560433 Administering a nuclear factor kappa Beta regulatory sequences |
| 07/14/2009 | US7560432 By introducing adhesive collagen-polyethylene glycol (PEG) hydrogel to site of injury alone, supplemented with synovial tissue or in conjunction with support matrix; arthroscopic surgery |
| 07/14/2009 | US7560431 administering drug biological conjugates used for the diagnosis, prophylaxis, or treatment of nervous system disorders or lysosomal storage diseases; drug delivery; blood brain barriers |
| 07/14/2009 | US7560430 Elastin digest compositions and methods utilizing same |
| 07/14/2009 | US7560429 Bioavailability; freeze-dried packages |
| 07/14/2009 | US7560428 Hair growth promoting oligopeptides |
| 07/14/2009 | US7560426 Verotoxin pharmaceutical compositions and medical treatments therewith |
| 07/14/2009 | US7560425 Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes |
| 07/14/2009 | US7560424 Localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper |
| 07/14/2009 | US7560287 Long wavelength engineered fluorescent proteins |
| 07/14/2009 | US7560265 Compositions for regulation of tumor necrosis factor-alpha |
| 07/14/2009 | US7560263 Has greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL; enhances prokaryotic PAL catalytic activity and stability while reducing immunogenicity and/or proteolytic sensitivity of prokaryotic PAL |
| 07/14/2009 | US7560253 Detecting level of expression of a hemopoietic linkage switch-5 (HLS-5) polynucleotide in a biological sample from a suspected or known cancer patient |
| 07/14/2009 | US7560249 The substrate comprises a carbon source comprising ethanol and an inducer |
| 07/14/2009 | US7560247 Nucleic acids encoding anti-IL-12 antibodies, and methods of production |
| 07/14/2009 | US7560132 Oilseed processing |
| 07/14/2009 | US7560107 Antihemophilic factor for use in the treatment of blood disorders; corrects hemophilia in a patient deficient in factor VIII or having inhibitors to factor VIII |
| 07/14/2009 | US7560106 cleaving a heparin-like glycosaminoglycan using modified heparinases having altered binding specificity and activity; angiogenesis inhibition |
| 07/14/2009 | US7560105 Dendritic cells activated in the presence of glucocorticoid hormones are capable of suppressing antigen-specific T cell responses |
| 07/14/2009 | US7560102 Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease |
| 07/14/2009 | US7560101 Method of treatment of an infection in an animal with GM-CSF cysteine muteins in the proximal region to helix A |
| 07/14/2009 | CA2439858C Graft rejection suppressors |
| 07/14/2009 | CA2382302C A nucleic acid and encoding polypeptide for use in inhibiting tumor angiogenesis |
| 07/14/2009 | CA2331410C Methods for treating diabetes by inhibiting gdf-8 |
| 07/14/2009 | CA2262972C Compositions of plant carbohydrates as dietary supplements |
| 07/14/2009 | CA2242542C Compositions and methods for therapeutic use |
| 07/14/2009 | CA2235721C Lipopolyamines as transfection agents and pharmaceutical uses thereof |
| 07/10/2009 | CA2617691A1 Translocator component derivatives and uses thereof |
| 07/09/2009 | WO2009086516A1 Anti-proliferative compounds and their use |
| 07/09/2009 | WO2009086296A2 Counter-pressure filtration of proteins |
| 07/09/2009 | WO2009086202A2 Methods for treating neuropsychiatric conditions |
| 07/09/2009 | WO2009086166A1 Room temperature stable, lyophilized natriuretic peptide formulations |
| 07/09/2009 | WO2009086131A1 Bmp mutants with decreased susceptibility to noggin |
| 07/09/2009 | WO2009085475A1 Method for detection and treatment of aneurysms |
| 07/09/2009 | WO2009085443A1 Topical compositions containing desthiobiotin and its derivatives and a method of treating skin |
| 07/09/2009 | WO2009085317A1 Disinfectant compositions, methods and systems |
| 07/09/2009 | WO2009085096A2 Non-leaching, non-fouling antimicrobial coatings |
| 07/09/2009 | WO2009085058A1 Cosmetic cleanser |
| 07/09/2009 | WO2009084739A1 Method and pharmaceutical composition for treatment of cancer using bmp10 protein, |
| 07/09/2009 | WO2009084738A1 Method and pharmaceutical composition for treatment of cancer using bmp9 protein |
| 07/09/2009 | WO2009084732A1 Agent for alleviating adverse side effects produced in interferon/ribavirin combination therapy |
| 07/09/2009 | WO2009084232A1 Sugar chain-related gene and use thereof |
| 07/09/2009 | WO2009084044A1 Composition comprising superoxide dismutase and carboxv methyl beta-1,3 glucan |
| 07/09/2009 | WO2009083930A1 Caspase-8 inhibitors and uses thereof |
| 07/09/2009 | WO2009083929A1 Caspase-1 inhibitors and uses thereof |
| 07/09/2009 | WO2009083686A1 Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes |
| 07/09/2009 | WO2009083663A2 Cyclic peptides comprising at least one aza-β3-aminoacyl residue and uses thereof |
| 07/09/2009 | WO2009083621A1 Method for the production and purification of the factor derived from the pigmented epithelium of the retina in a yeast system |
| 07/09/2009 | WO2009083607A1 Pharmaceutical compositions comprising granules of purified microbial lipase and methods for preventing or treating digestive disorders |
| 07/09/2009 | WO2009083249A2 Synthetic analogs of human beta-defensins having antimicrobial, antiviral and chemotactic activity |
| 07/09/2009 | WO2009083203A2 Topical application and formulation of erythropoietin for skin wound healing |
| 07/09/2009 | WO2009083188A2 Compositions and methods for prophylaxis and treatment of cellular degenerative disorders |
| 07/09/2009 | WO2009083155A1 Substance containing at least one active ingredient that has a gum-growing effect |
| 07/09/2009 | WO2009067639A3 Variants of c-type natriuretic peptide |
| 07/09/2009 | WO2009067407A3 Compositions of matrix metalloproteinase activating endopeptidases for reducing intraocular pressure, and methods of use thereof |
| 07/09/2009 | WO2009067225A3 Boceprevir derivatives for the treatment of hcv infections |
| 07/09/2009 | WO2009052942A3 Stabilization of hydrophobic protein therapeutic agents |
| 07/09/2009 | WO2009048778A3 Laminins, derivatives, and compositions including same and method for their therapeutic use |
| 07/09/2009 | WO2009047728A3 New s-acyl-glutathione derivatives, their syntesis and use in the treatment of oxidative stress-related diseases |
| 07/09/2009 | WO2009046369A3 Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c |
| 07/09/2009 | WO2009043524A3 Use of a peptide as therapeutic agent |
| 07/09/2009 | WO2009042215A3 Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor |
| 07/09/2009 | WO2009036388A3 Gene signature for the prediction of radiation therapy response |
| 07/09/2009 | WO2009033814A3 Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent |
| 07/09/2009 | WO2009033764A3 Use of a peptide as a therapeutic agent |
| 07/09/2009 | WO2009033749A3 Use of thymopentin as a therapeutic agent |
| 07/09/2009 | WO2009033748A3 Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent |
| 07/09/2009 | WO2009031051A3 Stabilized anthocyanin compositions |
| 07/09/2009 | WO2009023355A3 Compositions and methods for reducing the toxicity of certain toxins |
| 07/09/2009 | WO2009015840A3 Polypeptide for targeting of neural cells |
| 07/09/2009 | WO2009009562A3 Glp-1-fc fusion protein formulation |
| 07/09/2009 | WO2008121830A8 Phage receptor binding proteins for antibacterial therapy and other novel uses |
| 07/09/2009 | WO2008040190A8 Small peptides for anti-angiogenesis and use thereof |
| 07/09/2009 | WO2008024919A8 Interferon antagonists, antibodies thereto, and associated methods of use |
| 07/09/2009 | WO2008000186A8 A method for identifying novel gene and the resulting novel genes |
| 07/09/2009 | WO2007129999A8 Antiproliferative peptides and antibodies for their detection |
| 07/09/2009 | WO2007112675A8 Vegf receptor fusion protein and use thereof |
| 07/09/2009 | WO2007098548A8 A molecule and chimeric molecules thereof |
| 07/09/2009 | WO2007098547A8 A molecule and chimeric molecules thereof |
| 07/09/2009 | WO2007095661A8 Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| 07/09/2009 | US20090178153 G protein coupled receptors and uses thereof |
| 07/09/2009 | US20090176973 Thrombopoietin mimetics |
| 07/09/2009 | US20090176964 Stabilized Alpha Helical Peptides and Uses Thereof |
| 07/09/2009 | US20090176746 4'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-3'-hydroxybiphenyl-4-carboxylic acid; Promotes thrombopoiesis and megakaryocytopoiesis |
| 07/09/2009 | US20090176722 Androgen-regulated PMEPA1 gene and polypeptides |
| 07/09/2009 | US20090176716 Inhibitors of cancer cell, t-cell and keratinocyte proliferation |
| 07/09/2009 | US20090176715 Pharmaceutical Compositions and Methods Utilizing a D-Amino Acid |
| 07/09/2009 | US20090176714 METHOD OF REDUCING THE EFFECTS OF ABeta AND COMPOSITIONS THEREFORE |
| 07/09/2009 | US20090176713 Co-Administration of an Agent Linked to an Internalization Peptide with an Anti-Inflammatory |
| 07/09/2009 | US20090176712 Peptides with Efficacy in Rescuing Melanocortin-4 Receptor Polymorphic Agonist Signaling |
| 07/09/2009 | US20090176711 Inhibitors of amyloid precursor protein processing |
| 07/09/2009 | US20090176710 Complex for transferring an anionic substance into a cell |
| 07/09/2009 | US20090176709 Process for obtaining a concentrate of von willebrand factor or a complex of factor viii/von willebrand factor and use of the same |
| 07/09/2009 | US20090176708 Chemically modified factor ix |
| 07/09/2009 | US20090176707 Human signal peptide-containing proteins |
| 07/09/2009 | US20090176706 Materials and methods for treatment of inflammatory and cell proliferation disorders |
| 07/09/2009 | US20090176705 Modular platform for targeted therapeutic delivery |